Paul Hastings Advised The Underwriters In Humacyte’s Common Stock Offering
Paul Hastings LLP advised TD Cowen, Barclays, BTIG, and others as underwriters in Humacyte’s (Nasdaq: HUMA) common stock offering of 25 million shares;
Paul Hastings Advised the Underwriters in Humacyte’s Common Stock Offering
Paul Hastings LLP advised TD Cowen, Barclays, and BTIG as joint book-running managers and H.C. Wainwright & Co. and The Benchmark Company as lead managers in Humacyte, Inc.’s (Nasdaq: HUMA) offering of 25,000,000 shares of common stock. The offering is expected to close on or about March 27, 2025, subject to customary closing conditions.
The Paul Hastings team was led by Seo Salimi (Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group) and Will Magioncalda (Partner), with support from Chris Guerin (Associate) and Adam Swank (Associate).
